Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.74 |
| ▸ | CASP1 | P29466 | 1/20 | 0.74 |
| ▸ | MYH9 | P35579 | 1/20 | 0.74 |
| ▸ | MYH10 | P35580 | 1/20 | 0.74 |
| ▸ | CASP7 | P55210 | 1/20 | 0.74 |
| ▸ | HBB | P68871 | 1/20 | 0.74 |
| ▸ | MYH2 | Q9UKX2 | 1/20 | 0.69 |
| ▸ | METAP2 | P50579 | 9/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21067295 | 1.00 | KMT2A (0.74) | KMT2AMEN1MAPTCYP3A4KDM4E | |
| SCHEMBL23000093 | 0.87 | MEN1 (0.65) | KMT2AMEN1MAPTCYP3A4KDM4E | |
| SCHEMBL26214101 | 0.87 | MEN1 (0.65) | KMT2AMEN1MAPTCYP3A4KDM4E | |
| SCHEMBL23137602 | 0.86 | MEN1 (0.67) | KMT2AMEN1MAPTCYP3A4KDM4E | |
| SCHEMBL30610330 | 0.86 | MEN1 (0.67) | KMT2AMEN1MAPTCYP3A4KDM4E | |
| SCHEMBL23137832 | 0.86 | MEN1 (0.66) | KMT2AMEN1MAPTCYP3A4KDM4E | |
| SCHEMBL23136657 | 0.86 | MEN1 (0.66) | KMT2AMEN1MAPTCYP3A4KDM4E | |
| SCHEMBL21067621 | 0.85 | MEN1 (0.83) | KMT2AMEN1MAPTCYP3A4KDM4E | |
| SCHEMBL4330341 | 0.85 | MEN1 (1.00) | KMT2AMEN1MAPTCYP3A4KDM4E | |
| SCHEMBL23235537 | 0.85 | MEN1 (0.76) | KMT2AMEN1MAPTCYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338240-B2 | Nonmuscle myosin ii inhibitors | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250163056-A1 | NONMUSCLE MYOSIN II INHIBITORS | THE UNIV OF FLORIDA RESEARCH FOUNDATION INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20230339959-A1 | PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS | EÖTVÖS LORÁND TUDOMÁNYEGYETEM (HU) | 2023-10-26 | — | — | US | disclosed |
| US-20230339959-A1 | PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS | EÖTVÖS LORÁND TUDOMÁNYEGYETEM (HU) | 2023-10-26 | — | — | US | disclosed |
| US-11746112-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | EÖTVÖS LORÁND TUDOMÁNYEGYETEM (HU) | 2023-09-05 | — | — | US | disclosed |
| US-11746112-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | EÖTVÖS LORÁND TUDOMÁNYEGYETEM (HU) | 2023-09-05 | — | — | US | disclosed |
| US-20230227452-A1 | NONMUSCLE MYOSIN II INHIBITORS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-11649234-B2 | Nonmuscle myosin II inhibitors for substance use relapse | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20210317117-A1 | NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-14 | — | — | US | disclosed |
| EP-3806854-A1 | NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE | The Scripps Research Institute (US) | 2021-04-21 | — | — | EP | disclosed |
| US-20210087201-A1 | PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS | EÖTVÖS LORÁND TUDOMÁNYEGYETEM (HU) | 2021-03-25 | — | — | US | disclosed |
| US-9994564-B2 | Myosin II ATPase inhibitor compounds | BLEBBICORP | 2018-06-12 | — | — | US | disclosed |
| US-9943512-B2 | Drug treatment of overactive bladder | BLEBBICORP, LLC | 2018-04-17 | — | — | US | disclosed |
| US-9827238-B2 | Drug treatment of overactive bladder | BLEBBICORP, LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170129886-A1 | MYOSIN II ATPASE INHIBITOR COMPOUNDS | BLEBBICORP | 2017-05-11 | — | — | US | disclosed |
| US-20170020861-A1 | DRUG TREATMENT OF OVERACTIVE BLADDER | BLEBBICORP, LLC | 2017-01-26 | — | — | US | disclosed |
| US-20160375003-A1 | DRUG TREATMENT OF OVERACTIVE BLADDER | BLEBBICORP, LLC | 2016-12-29 | — | — | US | disclosed |
| US-9492441-B2 | Drug treatment of overactive bladder | BLEBBICORP, LLC | 2016-11-15 | — | — | US | disclosed |
| US-9492441-B2 | Drug treatment of overactive bladder | BLEBBICORP, LLC | 2016-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163056-A1 | NONMUSCLE MYOSIN II INHIBITORS | MYH2, MYO3B, MYO1B | KMT2A 3765/4885MEN1 1652/4885MAPT 353/4885 |
| US-20210087201-A1 | PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS | MYH2, MYLK2, MYO1B | KMT2A 3113/4885MEN1 2122/4885MAPT 99/4885 |
| US-20170020861-A1 | DRUG TREATMENT OF OVERACTIVE BLADDER | MYH2, MYO3A, MYO1B | KMT2A 2525/4885MEN1 3399/4885MAPT 1959/4885 |
| US-20160375003-A1 | DRUG TREATMENT OF OVERACTIVE BLADDER | MYH2, MYO3A, MYO1B | KMT2A 2800/4885MEN1 3962/4885MAPT 2474/4885 |
| US-11746112-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | MYH2, MYLK2, MYO1B | KMT2A 3113/4885MEN1 2122/4885MAPT 99/4885 |
| US-20170129886-A1 | MYOSIN II ATPASE INHIBITOR COMPOUNDS | MYO3A, MYO3B, MYO1B | KMT2A 2398/4885MEN1 3057/4885MAPT 1974/4885 |
| US-20230227452-A1 | NONMUSCLE MYOSIN II INHIBITORS | MYH2, MYO3B, MYO1B | KMT2A 3765/4885MEN1 1652/4885MAPT 353/4885 |
| US-20210317117-A1 | NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE | MYH2, MYO3B, MYO1B | KMT2A 3769/4885MEN1 1418/4885MAPT 441/4885 |
| US-12338240-B2 | Nonmuscle myosin ii inhibitors | MYH2, MYO3B, MYO1B | KMT2A 3765/4885MEN1 1652/4885MAPT 353/4885 |
| US-20230339959-A1 | PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS | MYH2, MYLK2, MYO1B | KMT2A 3113/4885MEN1 2122/4885MAPT 99/4885 |
| US-11649234-B2 | Nonmuscle myosin II inhibitors for substance use relapse | MYH2, MYO3B, MYO1B | KMT2A 3769/4885MEN1 1418/4885MAPT 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.